Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care. Its current portfolio centers on NERLYNX, an oral treatment based on neratinib used in specific HER2-positive breast cancer settings, along with alisertib, an investigational oncology candidate being studied across several tumor types. The company works through specialty pharmacy and distributor networks and maintains licensing and collaboration agreements that support the development, manufacture, and commercialization of its cancer-focused products. Puma Biotechnology serves patients and healthcare providers in the United States and select international markets, with an emphasis on targeted therapies for oncology. Based in Los Angeles, California, Puma Biotechnology plays a specialized role in the biotechnology market by concentrating on molecularly targeted cancer treatments and late-stage product commercialization.